Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam tosylate versus propofol for emergency endoscopic treatment of portal hypertensive upper gastrointestinal bleeding in cirrhosis
ChiCTR2100048620Phase 4Not yet recruiting
- Sponsor
- Xuchang Central Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remimazolam and propofol in Cirrhosis and Portal Hypertension (PH) (4 arms), sponsored by Xuchang Central Hospital. Primary endpoints: Sedation induction time, Sedation recovery time and 3 more. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
remimazolampropofol
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on ChiCTR2100048620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048620.